Is Real-time CGM Superior to Flash Glucose Monitoring in Real Life Study (CORRIDA LIFE)
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)Device: Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)
- Registration Number
- NCT04759495
- Lead Sponsor
- Charles University, Czech Republic
- Brief Summary
The aim of the investigator's study is to compare real-time continuous glucose monitoring (rt-CGM) and flash glucose monitoring (FGM) in adult patients with Type 1 Diabetes (T1D) in real life practice during 24 weeks of follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 187
- patients with T1D naive to rt-CGM and FGM
- Type 1 diabetes for > 1 year
- ≥ 18 years old
- CSII without automatic functions or MDI
- previous rtCGM or FGM use
- treatment with insulin pump with automatic functions
- severe noncompliance
- known severe diabetic retinopathy and/or macular edema
- lactation, pregnancy, or intending to become pregnant during the study
- a condition likely to require MRI
- use of acetaminophen-containing medication
- unwillingness to use the study device for >70% of time
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description rtCGM Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring) Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring). FGM Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring) Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
- Primary Outcome Measures
Name Time Method Changes in glycated haemoglobin (HbA1c) Up to 13 months Differences between HbA1c values in the Run in period and after 12 month of follow-up and differences of HbA1c between groups.
- Secondary Outcome Measures
Name Time Method Incidence of severe ketoacidosis Up to 13 months Requiring hospitalization
Percentage of time in hyperglycemic ranges Up to 13 months \>10.0 mmol/L \[180 mg/dl\] and \>13.9 mmol/L \[250 mg/dl\]
Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor Up to 13 months Skin reaction, infection or hematoma reported by patients
Percentage of time in hypoglycemic ranges Up to 13 months \<3.9 mmol/L \[70 mg/dl\] and \<3.0 mmol/L \[54 mg/dl\]
Changes in glycemic variability Up to 13 months Expressed as the standard deviation
Mean sensor glucose concentration Up to 13 months Measured by rtCGM or FGM
Incidence of severe hypoglycaemia Up to 13 months Requiring third-party assistance to treat
Percentage of time in target ranges Up to 13 months 3.9-10.0 mmol/L \[70-180 mg/dl\]
Trial Locations
- Locations (1)
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University
🇨🇿Prague, Czechia